Arena Pharmaceuticals Inc

Arena Pharmaceuticals — Investor Presentation (August 2018)

33 slides from Arena Pharmaceuticals's investor presentation, Aug 9, 2018

  1. Slide 1: Corporate Presentation August 2018

    Corporate Presentation August 2018 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about the Arena investment thesis, catalysts, value, our investigative stage drug candidates, including with respect to their potential (including to become first or best-in-c

  3. Slide 3: Arena Investment Thesis

    *Leerink Analysis & Decision Resources 2016 Arena Investment Thesis Two potential best-in-class, internally developed drug candidates to Ph 3 Olorinab data readout in Crohn’s pain in September Ralinepag Ph 3 program initiated in PAH; OLE data in H2 Etrasimod Ph 3 initiation in UC Etrasimod program i

  4. Slide 4: Differentiated Assets with High-Value Potential

    Differentiated Assets with High-Value Potential Current Publicly Disclosed Pipeline Program Therapeutic Area/Indication PC Ph 1 Ph 2 Ph 3 Status Etrasimod Optimized Activity S1P Receptor Modulator Ulcerative Colitis (UC) Study 1 Ph 3 Planning Ulcerative Colitis (UC) Study 2 Ph 3 Planning Crohn’s Dis

  5. Slide 5: Etrasimod

    Oral, Next Generation, S1P Receptor Modulator with Optimized Activity Being Evaluated for Multiple Immune-Inflammatory Diseases Etrasimod

  6. Slide 6: Etrasimod Phase 2 efficacy and safety summary

    Ph 2 Efficacy Dose dependent lymphocyte reduction Strong remission data – 33% of 2 mg patients achieved remission with heavy pretreatment with biologics Strong and consistent mucosal healing Fast onset - important in flare state Novel orals Existing biologics S1Ps JAKs $18-23B IBD Market Globally1 P

  7. Slide 7: S1P Modulation May Avoid Off-Target Activity

    S1P Modulation May Avoid Off-Target Activity S1P = Sphingosine 1-phosphate; UC = ulcerative colitis. *Data generated at Arena or under sponsored research by Arena Etrasimod’s Highly Selective Etrasimod Decreased Inflammation & Improvement in Immune-Inflammatory Disorders Positive Outcome Negative Ou

  8. Slide 8: Etrasimod Does Not Induce S1PR2 Internalization

    Etrasimod Does Not Induce S1PR2 Internalization (In Vitro Studies) Arena Data presented at ASPET 2017 at Experimental Biology (EB); DMSO = dimethylsulfoxide; S1P = sphingosine-1-phosphate In Contrast with Other S1P Modulators -12 -11 -10 -9 -8 -7 -6 -5 log [Agonist] (M) Mean Fluorescence Intensity (

  9. Slide 9: Receptor Pharmacology and Endothelial Barrier Function

    Montrose et al. S1P1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. J Lipid Res. 2013 Mar; 54(3): 843–851; Spiegel S et al. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Immunology Rev (2011); Blackenbach KV et al., Frontiers in Ph

  10. Slide 10: S1P1 Signaling Profile and Barrier Function

    Ungaro et al. Lancet 2017; 389:1756-70. Baumgart & Sandborn Lancet 2012; 380:1590-1605. Jain & Bhatti Neurology 2012;78:672-689. Sanna et al Nat Chem Biol 2006;2:434-441. Etrasimod’s S1P1 Signaling Profile May Have Beneficial Effects on Barrier Function Implications for Efficacy Better mucosal heali

  11. Slide 11: Etrasimod Has a Quick Offset of Action

    Ozanimod Similar to Gilenya; Etrasimod Only 2nd Generation Sources: 1-Tran JQ et al, J Clin Pharmacol. 2017;57:988-996. 2-Kovarik JM et al, J Clin Pharmacol. 2004;44:535-537. 3- ADP334 P1 Data on File; *Active metabolite Etrasimod Has a Quick Offset of Action Note – Data Collected from Separate Stud

  12. Slide 12: Etrasimod Has a Quick Onset of Action

    Phase 1 Data *After dose escalation of ozanimod (0.3 mg/d on days 1–3; 0.6 mg/d on days 4 and 5; 1 mg/d on days 6 and 7; and 3 mg/d on days 8–10. Data truncated at day 11 (ozanimod) and 15 (etrasimod) to show on-treatment onset effects Sources: 1-Tran JQ et al, J Clin Pharmacol. 2017;57:988-996. 2-

  13. Slide 13: Etrasimod Phase 2 Trial in Ulcerative Colitis (OASIS)

    Randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study Etrasimod Phase 2 Trial in Ulcerative Colitis (OASIS) 12-Week Induction Phase 12-Week Treatment Period Transition Directly into 36-Week Extension Study (APD334-005) 156 Patients Randomized 1:1:1 Week 14 Follow-up Safety

  14. Slide 14: Phase 2 Primary Endpoint: 3-Domain MCS

    Δ = -0.43 (p = 0.146) Placebo Etrasimod 1 mg Etrasimod 2 mg Δ = -0.99 (p = 0.009) Change on 9-Point Scale Including Rectal Bleeding, Stool Frequency, Endoscopy LS=least square; Δ LS mean difference from placebo. LS mean was estimated using an ANCOVA model that includes current oral corticosteroid th

  15. Slide 15: Phase 2 Secondary Endpoint: Endoscopic Improvement

    Δ = 4.1% (p = 0.306) Δ = 24.4% (p = 0.003) Proportion of Patients with Mayo Clinic Subscore of 0 or 1 points Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists Phase 2 Secondary Endpoint: Endoscopic

  16. Slide 16: Phase 2 Clinical Remission (3-Domain)

    Proportion of Patients with Endoscopy, Rectal Bleeding and Stool Frequency Mayo Clinic Subscore of ≤ 1 point and Stool Frequency Improvement of ≥ 1 point Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antago

  17. Slide 17: Phase 2 Clinical Remission (4-Domain) in UC

    Proportion of Patients with TMCS ≤ 2 points and No Subscore > 1 point Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists.. Sources: Ozanimod: Sandborn, et al. NEJM 2016;

  18. Slide 18: Clinical Remission (4-Domain) in UC Studies of S1P Modulators

    Proportion of Patients with with Total Mayo Clinic Score ≤ 2 points and No Subscore > 1 point Total MCS = Mayo Clinic Score. Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antag

  19. Slide 19: Phase 2 Safety Profile

    Phase 2 Safety Profile Etrasimod was generally safe and well tolerated Adverse events were predominantly mild to moderate No serious adverse events (SAEs) at the 2 mg dose Impact on HR and AV conduction was low throughout the study with no discontinuations related to bradycardia or AV block. No SAEs

  20. Slide 20: Ralinepag

    A Next-Generation, Oral, Selective Prostacyclin Receptor (IP) Agonist for the Treatment of Pulmonary Arterial Hypertension Ralinepag

  21. Slide 21: Potential to Redefine Treatment Paradigm in PAH

    Potential to Redefine Treatment Paradigm in PAH 1. Decision Resources 2016 2. Barst RJ N Engl J Med 1996; 334:296-301 *Least squares mean change from baseline; non parametric testing to account for non-normal distribution Phase 3 Ralinepag Oral QD Ralinepag 6.5-10x improved potency compared to selex

  22. Slide 22: Ralinepag's More Potent IP Agonism

    Vasodilation1 (Normal Human Tissue) Inhibition of SMC Proliferation2 (Human PAH Tissue) Platelet Inhibition3 (Normal Human Cells) Translates to Improved Tissue Responses vs. Selexipag* in Vitro *MRE-269 is the active metabolite of selexipag. cAMP, cyclic adenosine monophosphate; PAH, pulmonary arter

  23. Slide 23: Ralinepag's unique PK profile

    Ralinepag’s unique PK profile is expected to provide a low peak-to-trough ratio, approximating continuous IV infusion Compound t½ (Hr) Ralinepag ~20–26 hrs3 Selexipag 8 hrs2 Treprostinil 4.5 hrs1 Long T½ low peak to trough Short T½ high peak to trough Long T½ modified release 0 24 36 48 60 72 12 Tim

  24. Slide 24: Ralinepag Significantly Improved Pulmonary Vascular Resistance

    Ralinepag Significantly Improved Pulmonary Vascular Resistance (PVR); ITT Population Unprecedented Ph 2 Efficacy in Contemporary Patient Population Secondary Endpoint Percent change (SE) from baseline 25 15 5 -5 -15 -25 -35 Ralinepag (n = 40) -29.8% (P = 0.03)* -20.1% Placebo (n = 21) 9.6% Mean abso

  25. Slide 25: PVR Changes With Ralinepag and Historical Flolan

    *PVR, change in least squares mean from placebo; **Flolan: Barst et al NEJM 1996 Feb 1;334(5): 296-301 PVR Changes With Ralinepag and Historical Flolan® Note: No direct head-to-head data available - Caution advised when comparing data across clinical studies Ralinepag (n=40) Placebo (n=40) Placebo (

  26. Slide 26: PVR Changes With Ralinepag and Historical Selexipag

    ITT Study Populations *PVR, change in geometric mean expressed as a percentage of the baseline value; **Selexipag data from P2 study: Medical Review CDER Application: 207947Orig1s000 PVR Changes With Ralinepag and Historical Selexipag Placebo (n=10) Selexipag (n=33) Placebo (n=21) Ralinepag (n=40) -

  27. Slide 27: Phase 2 Safety and Tolerability

    Phase 2 Safety and Tolerability The overall safety and tolerability profile consistent with the known profile of the prostacyclin therapy class Adverse events that occurred most frequently on ralinepag were similar to the on-target effects expected for prostacyclin therapies: Headache, nausea, diarr

  28. Slide 28: Phase 3 Program Comprehensive Approach

    Ralinepag vs. Placebo + Current Therapy ~140 patients Evaluate peak oxygen uptake (VO2) via CPET 7-month fixed treatment duration 2:1 randomization Expect to initiate in Q4:18 Ralinepag vs. Placebo + Current Therapy ~700 patients Evaluate time to first clinical worsening event Event-driven duration;

  29. Slide 29: Olorinab

    Peripherally Restricted, Highly–Selective, Full Agonist to Cannabinoid 2 Receptor (CB2) Being Evaluated for Treatment of Pain Associated with Crohn’s Disease Olorinab

  30. Slide 30: Unmet Need in Non-Opioid Pain Management

    Status Ph 2 ongoing for the treatment of pain associated with Crohn’s disease, data Q3’18 Unmet Need in Pain Opioid epidemic is a public health emergency No drugs developed for the treatment of visceral pain including: Inflammatory bowel disease Interstitial cystitis Pancreatitis Endometriosis Chron

  31. Slide 31: CB2 Receptor Expression in the GI Tract

    CB2 receptors represent a pathophysiological mechanism in GI tract to regulate abnormal motility, modulate intestinal inflammation & limit visceral sensitivity/pain CB2 Receptor Expression in the GI Tract CB2 receptors located in target tissue, neurons & local immune cells in GI tract CB2 receptor a

  32. Slide 32: Arena Investment Thesis

    *Leerink Analysis & Decision Resources 2016 Arena Investment Thesis Two potential best-in-class, internally developed drug candidates to Ph 3 Olorinab data readout in Crohn’s pain in September Ralinepag Ph 3 program initiated in PAH; OLE data in H2 Etrasimod Ph 3 initiation in UC Etrasimod program i

  33. Slide 33: Thank You

    THANK YOU NASDAQ: ARNA

Arena Pharmaceuticals — Investor Presentation (August 2018) on 6ix